Compare
Aquestive Therapeutics, Inc. vs Verrica Pharmaceuticals Inc. vs Journey Medical Corp vs Nuvation Bio Inc.
| Latest fiscal year | Aquestive Therapeutics, Inc. AQST | Verrica Pharmaceuticals Inc. VRCA | Journey Medical Corp DERM | Nuvation Bio Inc. NUVB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $44.55M | $35.58M | $61.24M | $62.90M |
| Revenue growth (YoY) | -22.6% | +370.2% | +11.1% | +699.0% |
| Gross margin | 58.3% (computed) | n/a | 65.8% (computed) | n/a |
| Operating margin | -159.5% | -34.2% | -13.3% | -338.7% |
| Net margin | -188.1% | -50.3% | -18.7% | -325.3% |
| Net income | -$83.78M | -$17.89M | -$11.43M | -$204.63M |
| EPS (Diluted) | -$0.78 | -$1.68 | -$0.47 | -$0.60 |
| Operating cash flow | -$52.43M | -$17.63M | -$12.44M | -$173.43M |
| Free cash flow | -$52.99M | -$17.63M | n/a | n/a |
| Cash & equivalents | n/a | $30.15M | $24.09M | $164.09M |
| Total assets | $160.43M | $47.13M | $94.59M | $594.82M |
| Total liabilities | $194.09M | $22.39M | $62.74M | $289.11M |
| Shareholders' equity | -$33.66M | $24.74M | $31.85M | $305.72M |
| Return on year-end equity | n/a | -72.3% | -35.9% | -66.9% |
| Shares outstanding | 122.04M | 17.18M | n/a | 337.84M |
Revenue, most recent five fiscal years
| Fiscal year | Aquestive Therapeutics, Inc. | Verrica Pharmaceuticals Inc. | Journey Medical Corp | Nuvation Bio Inc. |
|---|---|---|---|---|
| Latest | $44.55M Ended 2025-12-31 | $35.58M Ended 2025-12-31 | $61.24M Ended 2025-12-31 | $62.90M Ended 2025-12-31 |
| 1 year earlier | $57.56M Ended 2024-12-31 | $7.57M Ended 2024-12-31 | $55.13M Ended 2024-12-31 | $7.87M Ended 2024-12-31 |
| 2 years earlier | $50.58M Ended 2023-12-31 | $5.12M Ended 2023-12-31 | $59.66M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $47.68M Ended 2022-12-31 | $9.03M Ended 2022-12-31 | $71.00M Ended 2022-12-31 | n/a |
| 4 years earlier | $50.83M Ended 2021-12-31 | $12.00M Ended 2021-12-31 | $63.13M Ended 2021-12-31 | n/a |